EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Targeting BCMA in multiple myeloma: designs, challenges, and future directions

Yi Hu, Yuetao Xie, Xiaodong Wang, Lufeng Yang, He Geng, Zugang Yi, Yao Zhang, Lin Ma, Fang Chen

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03913-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yi Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Shenzhen Children's Hospital, Shenzhen, 518038, Guangdong, China. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shenzhen Science and Technology Innovation Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the development of CAR T cell therapies designed to address this plasma cell cancer. Various CAR designs, utilizing different BCMA recognition domains, have yielded promising clinical results, leading to the approval of two BCMA-targeting CAR T cell therapies by the US Food and Drug Administration (FDA) for the treatment of MM. This review uniquely examines the BCMA CAR T cell landscape, emphasizing the design of recognition domains, clinical efficacy, and patient outcomes. It critically addresses emerging challenges such as antigen escape and toxicity profiles, which have surfaced alongside therapeutic advances. Moreover, the review spotlights cutting-edge developments, including dual-targeting CAR T strategies, advancements in CAR T cell manufacturing, and innovative allogeneic CAR T approaches utilizing healthy donor cells. By detailing both the breakthroughs and ongoing challenges in BCMA CAR T cell therapy, this review offers a comprehensive perspective on the current state and future possibilities of CAR T cell therapy for MM and its expanding role in treating hematologic malignancies and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaB-Cell Maturation AntigenImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimals

Stichwörter der Autor:innen

B cell maturation antigenChimeric antigen receptorImmunotherapyMultiple myelomaT cells

Substanzen

B-Cell Maturation AntigenReceptors, Chimeric AntigenTNFRSF17 protein, human

Autor:innen und Institutionen

  • Department of Anesthesiology, Shenzhen Children's Hospital, Shenzhen, 518038, Guangdong, China.
  • Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, 518038, Guangdong, China.
  • Department of Anesthesiology, Shenzhen Children's Hospital, Shenzhen, 518038, Guangdong, China. fangchen18938690929@gmail.com.

Förderung

  • Natural Science Foundation of Shenzhen Science and Technology Innovation Commission

Zitieren

APA

Hu, Y., Xie, Y., Wang, X., Yang, L., Geng, H., Yi, Z., Zhang, Y., Ma, L., & Chen, F. (2025). Targeting BCMA in multiple myeloma: designs, challenges, and future directions. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03913-0

Vancouver

Hu Y, Xie Y, Wang X, Yang L, Geng H, Yi Z, et al. Targeting BCMA in multiple myeloma: designs, challenges, and future directions. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03913-0

BibTeX
@article{Hu2025,
  author = {Hu, Yi and Xie, Yuetao and Wang, Xiaodong and Yang, Lufeng and Geng, He and Yi, Zugang and Zhang, Yao and Ma, Lin and Chen, Fang},
  title = {Targeting BCMA in multiple myeloma: designs, challenges, and future directions},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03913-0}
}
Kostenlos starten →